Literature DB >> 16543491

Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.

Masato Nishiwaki1, Katsunori Ikewaki, Giovanni Bader, Hassan Nazih, Minna Hannuksela, Alan T Remaley, Robert D Shamburek, H Bryan Brewer.   

Abstract

OBJECTIVE: Lecithin:cholesterol acyltransferase deficiency (LCAT-def) is characterized by low levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) and the accumulation of lipoprotein-X (LpX). Despite the low HDL, atherosclerosis is uncommon in LCAT-def. The decreased LDL would be a possible explanation but the underlying mechanism is not clear. In addition, the mechanism(s) for LpX accumulation is not known. The aim of the present study is to elucidate the mechanism(s) responsible for the low LDL and determine the plasma kinetics of LpX in LCAT-def. METHODS AND
RESULTS: We conducted a radiotracer study in LCAT-def (n=2) and normal controls (n=10) and a stable isotope study in one patient and other controls (n=7). LCAT-def LDL was catabolized faster than control LDL in the control subjects as well as in LCAT-def patients. Control LDL was catabolized faster in LCAT-def patients than the controls. The production rate of LDL apolipoprotein B-100 was normal in LCAT-def. The increased LDL apoB-100 catabolism was confirmed by a stable isotope study. LpX was catabolized more slowly in LCAT-def.
CONCLUSIONS: The decreased LDL in LCAT-def is attributable to an increased catabolism caused by a rapid catabolism of abnormal LDL and an upregulation of LDL receptor pathway. The decreased catabolism of LpX contributes to its accumulation in LCAT-def.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543491     DOI: 10.1161/01.ATV.0000217910.90210.99

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.

Authors:  Robert D Shamburek; Rebecca Bakker-Arkema; Bruce J Auerbach; Brian R Krause; Reynold Homan; Marcelo J Amar; Lita A Freeman; Alan T Remaley
Journal:  J Clin Lipidol       Date:  2015-12-23       Impact factor: 4.766

Review 2.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

Review 3.  Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Authors:  Xavier Rousset; Robert Shamburek; Boris Vaisman; Marcelo Amar; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

4.  Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers.

Authors:  I Castro-Ferreira; Rute Carmo; Sérgio Estrela Silva; Otília Corrêa; Susana Fernandes; Susana Sampaio; Rodrigues-Pereira Pedro; Augusta Praça; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2017-10-06

5.  Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.

Authors:  Akihiro Katayama; Jun Wada; Hitomi Usui Kataoka; Hiroko Yamasaki; Sanae Teshigawara; Takahiro Terami; Kentaro Inoue; Motoko Kanzaki; Kazutoshi Murakami; Atsuko Nakatsuka; Hitoshi Sugiyama; Norio Koide; Hideaki Bujo; Hirofumi Makino
Journal:  NDT Plus       Date:  2011-07-26

6.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.